Dialectical Behaviour Therapy for Eating Disorders With Comorbid Borderline Personality Disorder: A Systematic Review and Clinical Implications
Abstract
Objective: Borderline personality disorder (BPD) and eating disorders (EDs) frequently co-occur and are associated with heightened clinical severity and emotion dysregulation. This systematic review aimed to synthesize empirical evidence on the effectiveness of dialectical behaviour therapy (DBT) in improving eating disorder outcomes among individuals with comorbid BPD and EDs.
Method: A systematic literature search was conducted across Wiley, Web of Science, SpringerLink and Scopus databases in accordance with PRISMA 2020 guidelines. Studies were included if they examined DBT-based interventions in samples with comorbid BPD and EDs and reported quantitative outcomes. Eight studies met inclusion criteria. Risk of bias was assessed using Joanna Briggs Institute (JBI) checklists, and a structured narrative synthesis was performed.
Results: Across studies, DBT-based interventions were associated with reductions in eating disorder symptom severity, maladaptive eating behaviours (e.g., binge eating and purging) and self-harm. Baseline BPD symptom severity did not consistently predict poorer outcomes and, in some cases, was associated with greater early improvements. However, substantial heterogeneity in study design, sample characteristics and outcome measures was observed, and methodological quality varied across studies.
Conclusions: DBT appears to be a clinically relevant and promising transdiagnostic intervention for individuals with comorbid BPD and EDs. Nevertheless, the…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.